在EGFR-TKI耐药肺癌中,血统可塑性和组织学转变
Li Yieng Eunice Lau1,2, Anders Jacobsen Skanderup1, Aaron C Tan3,4
1Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore 138672, Singapore.
International journal of molecular sciences
|January 10, 2026
概括
血统可塑性允许癌细胞通过改变其类型来抵抗治疗,特别是在EGFR突变肺腺癌中. 了解这种转变是开发新治疗方法的关键.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 分子医学是分子医学.
背景情况:
- 血统可塑性,癌细胞的适应性重编程,是治疗耐药性的重要原因.
- 在EGFR突变肺腺癌 (LUAD) 中,这种可塑性往往导致组织学转化为小细胞肺癌 (SCLC),这是对氨酸激酶抑制剂 (TKIs) 的主要抵抗机制.
- 转变的瘤保留了EGFR突变,但变得独立于EGFR,表现出侵略性行为和不良结果.
研究的目的:
- 探索EGFR突变LUAD的血统可塑性的机制和影响.
- 研究癌细胞如何通过表型和组织学变化获得耐药性.
- 确定与血统可塑性相关的潜在治疗漏洞.
主要方法:
- 对最近关于血统可塑性的基因组,转录组和表观遗传研究的审查.
- 分析空间和单细胞分析数据,以了解瘤异质性.
- 利用功能模型和多omics方法来识别治疗点.
主要成果:
- 血统可塑性,包括组织学转化为SCLC,是EGFR突变LUAD中普遍存在的抵抗机制.
- 分子变化往往先于明显的组织学变化,表明早期的重编程.
- 观察到异质的轨迹和中间状态,表明复杂的适应途径.
- 正在确定与新型SCLC和经典LUAD不同的治疗漏洞.
结论:
- 血统可塑性是治疗EGFR突变LUAD的一个关键挑战,驱动对TKIs的抗性.
- 了解塑性分子基础和时间动态对于早期检测和向治疗至关重要.
- 开发解决可塑性驱动抗性的新型治疗策略对于改善患者的治疗结果至关重要.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.6K
相关概念视频
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K